Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI-573 plus aromatase inhibitor versus aromatase inhibitor alone in metastatic breast cancer
2011-000198-29Phase 2Completed
- Sponsor
- MedImmune
- Start
- Aug 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of dusigitumab in breast cancer (2 arms), sponsored by MedImmune. Primary endpoint: Phase 1b primary endpoint – safety and tolerability. Started Aug 2011; status: completed.
02
Drugs
dusigitumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2011-000198-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000198-29.